NOI_1160077.pdf

Synopsis – Notice of Intent to Sole Source

This synopsis is hereby issued in accordance with FAR Part 5.203 in response to the mandatory requirement for a 15 day notification. The purpose of this synopsis is to announce the Food and Drug Administration’s intent to negotiate a Firm Fixed Price sole source contract with RADIX BIOSOLUTIONS, LTD., located at 111 W Cooperative Way, Georgetown, TX 78626-7676 for the purpose of acquiring xMAP multiplex assay kits. The Government intends to negotiate solely with RADIX BIOSOLUTIONS per FAR 6.302-1, as no other source of supplies will satisfy agency requirements. The purpose of this requirement is to continue studies awarded under contract # HHSF223201510071A. The new requirement will demonstrate the reliability of xMAP multiplex assays obtained through the previously mentioned procurement which are currently undergoing single lab validation. The Food and Drug Administration intends to purchase the following quantities and items:

One hundred and fifty (150) xMap Assay Kits for Food Allergens valued at $ 210,000.00

THIS NOTICE IS NOT A REQUEST FOR COMPETITIVE PROPOSALS, however, interested firms may submit a capability statement in response to the above requirement with pricing information by January 8th, 2016 @ 4:30 PM Local Time to Christopher McGucken, Contract Specialist, Phone:

(240) 402-7599, Email: Christopher.McGucken@fda.hhs.gov. A determination not to open competition based responses to this notice is solely within the discretion of the Government.